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 99 
Research in context 100 
Evidence before this study 101 
Studies on hypothyroidism and hyperthyroidism implicate that adequate maternal thyroid hormone 102 
availability is required for optimal fetal growth and development. Studies on the association of mild 103 
thyroid function test abnormalities with birth weight report heterogeneous results. Some studies 104 
indicate that high FT4 concentrations are associated with lower birth weight which could have 105 
implications for the treatment target in women already on levothyroxine therapy. We searched 106 
Medline (Ovid), Embase.com, Web-of-Science, Cochrane CENTRAL and Google Scholar up to 107 
March 18th, 2018 and collected data on serum thyroid function tests and antibody status during 108 
pregnancy and birth weight from prospective cohort studies including treatment-naïve pregnant 109 
women. 110 
Added value of this study 111 
This individual participant data meta-analysis showed that subclinical hypothyroidism is associated 112 
with lower birth weight. We also identified that a higher maternal FT4, even within the normal range, 113 
is associated with lower birth weight and that isolated hypothyroxinaemia was associated with higher 114 
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birth weight. The association of FT4 with birth weight was more apparent in the second and third 115 
trimester as compared to the first trimester of pregnancy. 116 
Implications of all the available evidence 117 
There was a continuous negative association of maternal FT4 with birth weight that was most 118 
prominent in the second and third trimester of pregnancy. This implicates that there could be a 119 
potential risk of overtreatment when titrating levothyroxine to high-normal FT4 concentrations during 120 
pregnancy and emphasize the need for treatment monitoring during later pregnancy. 121 
 122 
Abstract 123 
Background Adequate transplacental passage of maternal thyroid hormone is important for 124 
normal fetal growth and development. Maternal overt hypothyroidism and hyperthyroidism 125 
are associated with low birth weight but there are still important knowledge gaps regarding 126 
the impact of subclinical thyroid function test abnormalities on birth weight, in general or 127 
during the late second and third trimester of pregnancy, remains unknown. The aim of this 128 
study was to examine associations of maternal thyroid function with birth weight. 129 
Methods For this individual-participant data meta-analysis we searched Medline (Ovid), 130 
Embase.com, Web-of-Science, Cochrane CENTRAL and Google Scholar from inception to 131 
March 18th 2018, and published open invitations to join the Consortium on Thyroid and 132 
Pregnancy, to identify prospective cohort studies with data on maternal thyroid function 133 
during pregnancy and birth weight. We excluded participants with multiple pregnancies, in 134 
vitro fertilization, pre-existing thyroid disease or thyroid medication usage, miscarriages and 135 
stillbirth. Main outcomes were small for gestational age (SGA), large for gestational age 136 
(LGA) (defined by the lowest or highest 10th population-specific percentile of birth weight 137 
standardized to gestational age and sex, respectively) and birth weight. We analysed 138 
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individual participant data using mixed-effects regression models adjusting for maternal age, 139 
body mass index, ethnicity, smoking, parity, gestational age at blood sampling, fetal sex and 140 
gestational age at birth (the latter two only in case of birth weight continuously). The study 141 
protocol was pre-registered at the International Prospective Register of Systematic Reviews 142 
(PROSPERO), number CRD42016043496. 143 
Results From 2,526 published reports, 36 cohorts met the inclusion criteria and were invited 144 
to participate of which 15 agreed and after addition of 5 unpublished datasets, a total of 20 145 
cohorts were included. After exclusions, the study population comprised 48,145 mother-child 146 
pairs of whom 1,275 (3·1%) had subclinical hypothyroidism (increased TSH with normal 147 
FT4) and 929 (2·2%) had isolated hypothyroxinaemia (decreased FT4 with normal TSH). 148 
Maternal subclinical hypothyroidism was associated with a higher risk of SGA compared to 149 
euthyroidism (11·8% vs. 10·0% respectively, adjusted risk difference 2·4% [95% CI, 0·4 to 150 
4·8]; odds ratio (OR) 1·24 [95% CI 1·04 to 1.48], P=0·015) and lower mean birth weight 151 
(adjusted risk difference -38g [95% CI -61 to -15], P=0·001) with a higher effect estimate for 152 
measurement in the 3rd trimester compared with the 1st or 2nd trimester. Isolated 153 
hypothyroxinaemia was associated with a lower risk of SGA compared to euthyroidism (7·3% 154 
vs. 10·0%, adjusted risk difference -2·9 [95% CI, -4·5 to -0·9]; OR, 0·70 [95% CI 0·55 to 155 
0·91], P=0·007) and higher mean birth weight (difference, 45g [95% CI 18 to 73], P=0·001). 156 
Each 1-SD higher maternal TSH concentration was associated with lower birth weight (-6g [-157 
10 to -2], per SD, P=0·003), with higher effect estimates in TPOAb-positive than TPO-158 
negative women (P for interaction=0·10). Each 1-SD higher FT4 concentration was 159 
associated with lower birth weight (-21g [95% CI -25 to -17] per SD, P<0·0001), with a 160 
higher effect estimate for measurement in the 3rd trimester compared with the 1st or 2nd 161 
trimester.  162 
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Interpretation Maternal subclinical hypothyroidism in pregnancy is associated with a higher 163 
risk of SGA and lower birth weight, whereas isolated hypothyroxinaemia is associated with 164 
lower risk of SGA and higher birth weight. There was an inverse, dose-response association 165 
of maternal TSH and FT4 (even within the normal range) with birth weight. These results 166 
advance our understanding of the complex relationships between maternal thyroid function 167 
and fetal outcomes, and should prompt careful consideration of potential risks as well as 168 
benefits of levothyroxine therapy during pregnancy.  169 
Funding This work was supported by replication studies grant 401.16.020 from the 170 




Birth weight is an important marker of fetal growth, development, nutrition and other in utero 173 
exposures. Low birth weight or being born small for gestational age (SGA) are major risk 174 
factors for neonatal mortality and morbidity, and are associated with a higher risk of non-175 
communicable diseases in later life.1-4 In contrast, being large for gestational age (LGA) is a 176 
risk factor for caesarean section, postpartum haemorrhage, new-born hypoglycaemia and 177 
obesity in later life.5-7 Thyroid hormone regulates fetal growth and development throughout 178 
gestation. Fetal thyroid hormone availability largely depends on the placental transfer of 179 
maternal thyroid hormone, particularly during the first 18-20 weeks of pregnancy.8 Overt 180 
maternal thyroid disease such as hypothyroidism or (pre-existing) Graves’ hyperthyroidism 181 
are well known risk factors for SGA and occur in 0·2% to 1% of pregnancies.8 Milder thyroid 182 
function test abnormalities such as subclinical hypothyroidism, hypothyroxinaemia and 183 
subclinical hyperthyroidism are up to ten times more frequent. Because some studies showed 184 
that mild thyroid function test abnormalities are associated with SGA or LGA9-12 but others 185 
did not13,14, it remains to be elucidated whether, or to what extent these are risk factors for 186 
SGA or LGA. 187 
 188 
Levothyroxine is commonly prescribed during pregnancy in all parts of the world for 189 
treatment of overt thyroid dysfunction.15-19 To date, it remains common practice to titrate 190 
levothyroxine therapy to high-normal free thyroxine (FT4) concentrations and/or low-normal 191 
TSH concentrations as the potential benefits are believed to outweigh potential harms, 192 
although the evidence for this remains poor. However, some observational studies suggest 193 
that already high-normal FT4 concentrations are associated with impaired fetal growth and 194 
lower birth weight, suggesting that levothyroxine treatment comes with the potential risk of 195 
overtreatment.20-25 The guidelines of the American Thyroid Association indicate that 196 
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treatment can be considered for mild thyroid function test abnormalities such as subclinical 197 
hypothyroidism or for thyroid peroxidase antibody (TPOAb) positive women with a TSH 198 
above 2·5 mU/L, and is recommended for TPOAb positive women when the TSH is >4 mU/L 199 
and for all women when the TSH is >10 mU/L.26 Overall, previous observational studies on 200 
the association of mild thyroid function test abnormalities with birth weight show conflicting 201 
results10,26-32 and most randomized trials of levothyroxine treatment do not report any 202 
differences.33-37 Thus far, the interpretation of individual observational studies and 203 
randomized trials has been limited by the relatively small sample sizes and use of widely 204 
varying definitions of an abnormal thyroid function test. The latter, in combination with 205 
different definition of birth weight outcomes, different analysis approaches and scarcity of 206 
reporting results for isolated hypothyroxinaemia or continuous association of thyroid function 207 
with birth weight, limits the capabilities of an aggregate data meta-analysis. Furthermore, 208 
most studies have focused on early pregnancy, and both the clinical relevance of mild thyroid 209 
function test abnormalities as well as treatment aims for the second half of pregnancy remain 210 
to be elucidated.  211 
The aim of this study was to investigate the associations of maternal thyroid function tests 212 
with SGA, LGA and birth weight. 213 
 214 
Methods 215 
The Consortium on Thyroid and Pregnancy is a collaboration of prospective birth cohorts that 216 
aims to study the association of maternal thyroid function and autoimmunity with adverse 217 
pregnancy and child outcomes.38 For the current study, we followed the Preferred Reporting 218 
Items for Systematic Reviews and Meta-Analyses for Individual Patient Data guidelines and 219 
pre-registered our study protocol (PROSPERO ID CRD42016043496, appendix p3-6). To 220 
identify studies for inclusion, we conducted a systematic search of literature for the 221 
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publications on the association of thyroid function or autoimmunity with birth weight, 222 
published from inception to March 18th 2018, with no language restrictions using several 223 
databases (Medline (Ovid), Embase.com, Web-of-Science, Cochrane CENTRAL and Google 224 
Scholar, detailed search terms and strategy are in the appendix p7-8). We included cohort 225 
studies in which data was collected prospectively and that consecutively included participants 226 
from the general population and/or without active selection based on health status and had 227 
either TSH or FT4 measurements and data on birth weight available. We excluded studies in 228 
which participants received treatment based on (abnormal) thyroid function tests 229 
(predominantly hospital-based cohorts) or studies that only included women with (overt) 230 
thyroid disease. Possible studies for inclusion were independently assessed for suitability by 231 
two authors (TIMK and PNT) and any disagreement was resolved by discussion with a third 232 
author (RPP). Investigators from each eligible study were invited to join the consortium using 233 
the contact details on the identified reports; if unsuccessful we used contact details of other 234 
published studies, contacted their co-authors or department. Upon participation, we collected 235 
individual-participant data using a standardized codebook. Quality of the studies and risk of 236 
bias was assessed using the Newcastle-Ottawa scale. All cohorts were approved by a local 237 
review board and acquired participant informed consent or had been granted exemption from 238 
it by the local Ethics Committee. All participants with a measurement of TSH, FT4 or TPOAb 239 
(first available) and birth weight were included; any data on thyroglobulin antibodies (TgAb) 240 
was collected upon availability. We excluded participants with a miscarriage/stillbirth, pre-241 
existing thyroid disease or thyroid-interfering medication usage, IVF treatment or twin 242 
pregnancies. See appendix p8 for more details on methods. 243 
Exposures 244 
Exposures included subclinical thyroid function test abnormalities, continuous thyroid 245 
function test measurements (TSH and FT4), TPOAb and/or TgAb positivity. Overt 246 
10 
 
hyperthyroidism was considered as a subclinical disease entity, considering the transient 247 
nature and lack of indication for treatment with anti-thyroid drugs of this biochemically 248 
defined entity. We did not have data on TSH receptor antibodies or undiagnosed Graves’ 249 
disease, however, we considered this unlikely to affect our results given the prevalence of 250 
approximately 0.05%. We did not study the association of overt hypothyroidism with birth 251 
weight because treatment for this disease entity is non-controversial, and because the very low 252 
prevalence in combination with a relatively large number of women excluded because of pre-253 
existing thyroid disease indicates that women with true overt hypothyroidism are only 254 
selectively represented in the included studies. Thyroid function test abnormalities were 255 
defined according to cohort-specific 2·5th and 97·5th percentiles for TSH and FT4, in cohorts 256 
with TPOAb data, after exclusion of TPOAb positive women. Subclinical hypothyroidism 257 
was defined as TSH above the 97·5th percentile and a FT4 within the normal range (2·5th-258 
97·5th percentile). Overt hyperthyroidism was defined as TSH below the 2·5th percentile and a 259 
FT4 above the 97·5th percentile. Subclinical hyperthyroidism was defined as a TSH below the 260 
2·5th percentile and a FT4 within the normal range. Isolated hypothyroxinaemia was defined 261 
as a FT4 below the 2·5th percentile and a TSH within the normal range. TPOAb and TgAb 262 
positivity were based on cohort-specific cut-offs. For continuous TSH and FT4 concentrations 263 
as exposure variables, concentrations for all cohorts were log-transformed and then converted 264 
to population-specific standard deviation (SD) scores after removal of outliers (+/- 4 SD from 265 
the mean) to enable comparison between different cohorts and assays. 266 
Outcomes  267 
The primary outcomes were SGA, LGA and birth weight (as a continuous variable). To define 268 
SGA and LGA, birth weight was standardized according to gestational age at birth and fetal 269 
sex per cohort. SGA was defined as a standardized birth weight below the 10th cohort-specific 270 
percentile, and LGA as a standardized birth weight above the 90th cohort-specific percentile, 271 
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according to the definition of the World Health Organization.39 Secondary outcomes were low 272 
birth weight (LBW; birth weight below 2,500 grams) and macrosomia (birth weight above 273 
4,000 grams).  274 
 275 
Statistical analyses 276 
Datasets were merged and all analyses were performed according to the protocol, unless 277 
stated otherwise (appendix p8-9). We used linear mixed effect regression models with a 278 
random intercept for each cohort to study the association of thyroid function test 279 
abnormalities (compared with euthyroidism), TSH, FT4 concentrations or TPOAb, TgAb 280 
positivity with birth weight. We used generalized logistic mixed regression models with a 281 
random intercept for each cohort to study the association of thyroid function test 282 
abnormalities (compared with euthyroidism), TSH, FT4 concentrations or TPOAb, TgAb 283 
positivity with SGA, LGA, LBW and macrosomia. All analyses of primary outcomes were 284 
also performed using a two-step approach with random-effect models according to 285 
DerSimonian and Laird to pool estimates of the cohorts and assess heterogeneity across 286 
studies using the I2 statistic and 95% confidence interval. We evaluated for potential 287 
publication bias using funnel plots and Egger tests. All models were adjusted for maternal 288 
age, BMI, ethnicity, smoking, parity, gestational age at blood sampling, fetal sex and 289 
gestational age at birth (the latter two in case of birth weight, LBW and macrosomia outcomes 290 
only). To assess the effects of potential confounding, we ran crude models for the primary 291 
analysis. Risk differences and corresponding 95% CIs were calculated according to 292 
Newcombe and Bender, taking into account baseline risk imprecision calculated using the 293 
Wilson score method, and were adjusted for covariates and could thus deviate from non-294 
adjusted percentages.40 We used multilevel multiple imputation for missing data on covariates 295 
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creating five imputed datasets for pooled analyses.41 See appendix p8-9 for more details on 296 
statistical analysis and list of sensitivity analyses. 297 
All statistical analyses were performed using R statistical software version 3.5.1 (R 298 
Development Core Team (2018), Vienna, Austria; packages lme4, mice, micemd, metafor, 299 
sjPlot). 300 
The funder of the study had no role in study design, data collection, data analysis, data 301 
interpretation, or writing of the report. The corresponding author had full access to all of the 302 
data and the final responsibility to submit for publication. 303 
 304 
Results 305 
We identified 2,526 reports of which 133 were eligible for inclusion based on title and 306 
abstract screening (Figure 1). After reading full texts, and addition of five cohorts identified 307 
via personal contacts and open invitations, a total of 36 cohorts were invited to participate. 308 
Subsequently, 20 cohorts from Europe, USA, Chile, Pakistan, Japan and Australia responded 309 
to our invitation and were able to participate. After exclusions, the final study population 310 
included 48,145 participants (Figure 1) with a mean birth weight of 3,400 (SD 536) grams and 311 
median gestational age at birth of 39·9 (95% range: 35·5 to 42·0) weeks; 4,771 new-borns 312 
were born SGA (9·8%) and 4,736 (9·7%) were born LGA (Table). Subclinical 313 
hypothyroidism occurred in 1,275 women (3·1%), isolated hypothyroxinaemia occurred in 314 
929 women (2·2%) out of 41,564  from 17 cohorts with available data on TPOAbs. Cohort-315 
specific characteristics are provided in the appendix p10-17. Compared with participants 316 
included in the study, women who were not included because of missing data on birth weight 317 
had similar TSH and FT4 concentrations, but a higher rate of TPOAb positivity (12·6% vs. 318 




Compared with euthyroidism, maternal subclinical hypothyroidism was associated with a 321 
higher risk of SGA (11·8% vs 10·0%, adjusted risk difference 2·4 % [95% CI, 0·43 to 4·8]; 322 
odds ratio [95% CI]: 1·24 [1·04 to 1·48, P=0·015]; Figure 2A) and lower mean birth weight 323 
(estimated mean difference -38g [95% CI -61 to -1]; Figure 2C). Isolated hypothyroxinaemia 324 
was associated with a lower risk of SGA (7·3% vs 10·0%, adjusted risk difference -2·9 % 325 
[95% CI, ‐4·5 to ‐0·9]; odds ratio [95% CI]: 0·70 [0·55 to 0·91, P=0·007]; Figure 2A) and 326 
higher mean birth weight (estimated mean difference 45g [95% CI 18 to 73]; Figure 2C). 327 
Subclinical hyperthyroidism and overt hyperthyroidism were not associated with SGA or birth 328 
weight (Figure 2A), and there was no association of thyroid function test abnormalities with 329 
LGA (Figure 2B). 330 
 331 
When analysed as a continuous variable, each 1-SD higher maternal TSH concentration was 332 
associated with a higher risk of SGA (OR 1·05 [95% CI 1·01 to 1·08] per SD, Figure 3A) and 333 
lower mean birth weight (-6g [95% CI -10 to -2] per SD, Figure 3B). Each 1-SD higher FT4 334 
concentration was associated with a higher risk of SGA (OR 1·07 [95% CI 1·0 to 1·11] per 335 
SD, Figure 3A), a lower risk of LGA (OR 0·91 [95% CI 0·88 to 0·94] per SD, Figure 3A) and 336 
lower mean birth weight (-21g [95%CI -25 to -17] per SD, Figure 3B). When considered 337 
across the full FT4 range, the approximated difference in birth weight was ~200 grams 338 
(Figure 3B). Effect estimates remained similar when analyses were confined to TSH or FT4 339 
concentrations within the normal range (Figure 3B). TPOAb and TgAb positivity were not 340 
associated with SGA, LGA or birth weight (appendix p19). 341 
The association of FT4 with birth weight differed according to the gestational age at blood 342 
sampling (P for interaction=0·0002). Subsequent stratified analyses showed that the effect 343 
estimates of the association of FT4 with birth weight were 2 and 3-times larger when the FT4 344 
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concentration was measured during the 2nd or 3rd trimesters compared to the 1st trimester (β 345 
[95% CI] for birth weight: -13 , -22  and -36 in 1st, 2nd and 3rd trimesters, respectively; Figure 346 
4, appendix p21). Also, estimates of the association of subclinical hypothyroidism with birth 347 
weight measured in 2nd and 3rd trimesters were 2 and 5 times larger compared to 1st trimester 348 
(β [95% CI] for birth weight: -20 , -33  and -75 in 1st, 2nd and 3rd trimesters, respectively; 349 
appendix p21).  350 
 351 
There was evidence that the association of TSH and FT4 with birth weight differed according 352 
to TPOAb status (P for interaction=0·10 and 0·09, respectively). In the subsequent stratified 353 
analysis, effect estimates of the negative association of TSH with birth weight were 4-times 354 
higher for TPOAb positive women than TPOAb negative women (β [95% CI] -17g [-32 to -355 
2·5] per SD vs. -4.7g [-9 to -0·2] per SD, respectively; appendix p24&37). In contrast, for 356 
FT4, the negative effect estimate of the association with birth weight in TPOAb positive 357 
women was almost half the estimate for TPOAb negative women (β [95% CI] -10 [-25 to 4] 358 
per SD vs. -21 [-26 to -17] per SD, respectively; appendix p24&37).   359 
 360 
There was evidence that association of FT4 with birth weight differed according to maternal 361 
age and BMI (P for interaction 0·078 and 0·003, respectively) but not fetal sex or smoking 362 
status (appendix p20). When stratified by maternal age there was not a meaningful difference 363 
in the association of FT4 with birth weight between the two groups (β [95% CI] for birth 364 
weight: -22 [-27 to -17] and -19 [-25 to -13] for maternal age <30 or ≥30 years, respectively; 365 
appendix p22). Stratified analyses showed that the negative effect estimate of the association 366 
of FT4 with birth weight was larger in women with a BMI ≥30 kg/m2 compared to those with 367 
a BMI of 18-25 kg/m2 (appendix p23). There was also evidence that the association of TSH 368 
with birth weight differed according to maternal age (P for interaction=0.11) but not 369 
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gestational age at the time of sampling, fetal sex, BMI, or smoking (appendix p20). When 370 
stratified by maternal age, the negative association of TSH with birth weight was nearly 4-371 
times higher for women aged ≥30 years compared to <30 (appendix p22). Results of analyses 372 
on low birth weight or macrosomia yielded results similar to those of SGA or LGA (appendix 373 
p25-26). Additional adjustment for gestational diabetes mellitus or preeclampsia did not 374 
change the results (appendix p27-32). Results of the crude analyses can be found in appendix 375 
p33-34. Using Newcastle-Ottawa Quality Assessment Scales we did not identify any risk of 376 
bias in the included cohorts (appendix p35-36). Results of two-step meta-analyses were 377 
similar to one-step analyses with I2 statistics ranging between 0 to 51·5% indicative of low to 378 
moderate heterogeneity. Moreover, funnel plots did not indicate publication bias or 379 
unexpected differences in effect estimates between the included studies (appendix p38-45). 380 
Discussion 381 
In this individual participant data meta-analysis, we show that, compared to euthyroidism, 382 
maternal subclinical hypothyroidism during pregnancy is a risk factor for SGA and is 383 
associated with lower birth weight. By contrast, isolated hypothyroxinaemia was associated 384 
with higher birth weight but not LGA. Maternal TSH and FT4 concentrations were both 385 
inversely associated with birth weight, with the association of FT4 being most apparent 386 
during later pregnancy, whereas the association of TSH with birth weight was most apparent 387 
in TPOAb-positive women. 388 
 389 
One of the main results of this study is that higher FT4 concentrations are associated with 390 
lower birth weight, even within the normal range. For TSH concentrations, the associations 391 
with birth weight were less evident and not present within the normal range. These continuous 392 
analyses can be interpreted in various ways. First, together with results from other studies, the 393 
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negative association of maternal FT4 with birth weight in this study can strengthen 394 
hypotheses about the effects of thyroid hormone on the developing fetus. Since circulating 395 
maternal FT4 crosses the placenta, and maternal FT4 concentrations are correlated with new-396 
born FT4 concentrations,42,43 the negative association of maternal FT4 with birth weight could 397 
reflect a direct thyroid hormone effect. The negative dose-dependent association of FT4 with 398 
birth weight can also be further extrapolated to fetal growth restriction typically seen in 399 
pregnancies complicated by Graves’ hyperthyroidism.44,45 We hypothesize that such an effect 400 
is mediated by an increase in new-born lipid and protein catabolism causing a reduction in 401 
caloric availability, which could be further complicated by a higher placenta vascular 402 
resistance.46,47 Yet, the point estimates for overt hyperthyroidism in this study warrant further 403 
studies, although it is possible that the association of FT4 concentrations with birth weight is 404 
partly caused by high hCG concentrations. Overt hyperthyroidism in the current study may 405 
reflect transient gestational thyrotoxicosis rather than Graves’ hyperthyroidism, and high hCG 406 
concentrations have been associated with a higher birth weight.48 An alternative underlying 407 
mechanism could be through lower T3, as a recent study showed that lower maternal T3 is 408 
associated with lower birth weight.22 Although it remains to be elucidated whether T3 passes 409 
the placenta, further studies on the association of maternal T3 concentrations with pregnancy 410 
outcomes seem warranted also because T3 concentrations are lower in individuals treated 411 
with levothyroxine therapy.26 412 
Second, the continuous analyses for FT4 and TSH support the associations identified for 413 
isolated hypothyroxinaemia in this study, since both lower FT4 concentrations as well as 414 
isolated hypothyroxinaemia were associated with higher birth weight. Interestingly, the 415 
association of subclinical hypothyroidism with birth weight was in the opposite direction of 416 
the association of continuous FT4 and isolated hypothyroxinaemia, and TSH in the normal 417 
range (as is the case for isolated hypothyroxinemia) was not associated with birth weight. This 418 
17 
 
suggests important differences in the underlying pathophysiological mechanisms. Subclinical 419 
hypothyroidism is more common in TPOAb positive women and likely reflects a lower 420 
thyroid functional capacity. The latter is reflected by a considerable attenuation of the hCG-421 
mediated increase in FT4 and decrease in TSH concentrations in women with subclinical 422 
hypothyroidism as compared to euthyroid women.49 On the other hand, neither TPOAb 423 
positivity nor an impaired thyroidal response to hCG seem to play a role in women with 424 
isolated hypothyroxinaemia.49 We speculate that isolated hypothyroxinaemia is a thyroid 425 
function test abnormality that is specific for pregnancy and may not necessarily represent 426 
thyroid gland hypofunction.8 It has also been suggested that minor aberrations of thyroid 427 
function during pregnancy may arise from dysfunction of the uteroplacental unit, rather than 428 
from thyroid dysfunction.50 Further studies are required to elucidate the underlying 429 
physiology of such gestational thyroid function test abnormalities. 430 
Thyroid hormone regulates different metabolic and anabolic processes in both mother and 431 
fetus throughout gestation. It controls fetal growth by facilitating placentation and regulation 432 
of metabolism, fetal glucose and oxygen consumption as well as other co-factors directly 433 
affecting skeletal growth, tissue differentiation and accretion.51-53 One of the sensitivity 434 
analyses in this study showed that the negative association of FT4 with birth weight is 435 
amplified during the 2nd and 3rd trimester. These differences most likely reflect an 436 
amplification of the metabolic effect of thyroid hormone on fetal growth due to an increased 437 
fetal nutritional demand and increased fetal growth rate associated with the progression of 438 
pregnancy.51,54 Our results indicate that maternal thyroid function also during later pregnancy 439 
is a relevant determinant of fetal development. These results highlight the relevance of 440 
follow-up thyroid function testing when levothyroxine therapy is started during early 441 




Worldwide, levothyroxine is one of the most often prescribed drugs during pregnancy 15-19, 444 
and the dosage is commonly targeted to achieve high-normal FT4 concentrations. The 445 
extrapolation of data from population-based studies for defining treatment targets remains 446 
valuable, as is reflected by recent data on levothyroxine overtreatment and child 447 
neurocognition.8,55 This study in untreated, otherwise healthy women shows that a higher 448 
maternal FT4 concentration within the normal range is associated with lower birth weight and 449 
a higher risk of SGA. This suggests that levothyroxine therapy comes with a potential risk of 450 
overtreatment, especially when targeting high-normal FT4 concentrations. Consistent with the 451 
results of this study, a recent randomized trial showed that low-dose levothyroxine treatment 452 
of either subclinical hypothyroidism or isolated hypothyroxinaemia was associated with a 453 
higher risk of SGA, albeit statistically non-significant (for subclinical hypothyroidism, 454 
levothyroxine 10% vs placebo 8%; for isolated hypothyroxinaemia, levothyroxine 9% vs 455 
placebo 8%).37 Further studies are needed to investigate whether the changes in TSH or FT4 456 
concentrations that occur during levothyroxine therapy in pregnancy are related to treatment 457 
benefits and/or harms and differ per underlying thyroid function test abnormality. 458 
Strengths and limitations 459 
In the current study, we were able to utilize detailed individual-participant data on thyroid 460 
function, birth weight and potential confounders from 19 prospective, population-based 461 
cohorts, allowing standardization of the definition of thyroid function test abnormalities and 462 
analysing potential dose-dependent associations. One of the limitations of the current study is 463 
the interpretation of the results on overt hyperthyroidism, since we had limited statistical 464 
power for this group and TSH receptor antibody concentrations were not available. Secondly, 465 
the interpretation of the results could be affected by pregnancy-related changes in thyroid 466 
binding proteins that could interfere with FT4 immunoassays. However, gestational changes 467 
in FT4 concentrations as assessed by immunoassays are highly similar to those measured with 468 
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liquid chromatography-mass spectrometry or equilibrium dialysis.56,57 Thirdly, we could not 469 
invite 5 studies that were published while conducting statistical analyses for the current study 470 
(appendix p8) and that we could not collect data on previous stillbirths, renal disease or 471 
previous SGA. Finally, due to the observational nature of the included studies, we cannot 472 
exclude any residual or unmeasured confounding, which limits any conclusions on causality 473 
of the identified associations. 474 
Conclusion 475 
This large individual participant data meta-analysis shows that subclinical hypothyroidism is a 476 
risk factor for SGA and that isolated hypothyroxinaemia is associated with higher birth 477 
weight. Furthermore, we identified a dose-dependent negative association of maternal FT4 478 
with birth weight that was most prominent during late pregnancy. This indicates that there is a 479 
potential risk of overtreatment when titrating levothyroxine to high-normal FT4 480 
concentrations and underlines the importance of follow-up thyroid function testing when 481 
levothyroxine therapy is started during early pregnancy.  482 
 483 
Author Contributions 484 
AD, TIMK and MM performed analyses and were involved in writing of the manuscript. 485 
PNT, CMD, EAPS, LC, EKA, TIMK and RPP made the analysis plan and were involved in 486 
the writing of the manuscript. WMB performed the systematic search and PNT, TIMK and 487 
RPP were involved in study selection. All other authors were involved in data collection and 488 
provided substantial contributions to drafting of the work including critical revision for 489 
important intellectual content. TIMK and RPP supervised analyses, were involved in writing 490 
of the manuscript and directed the project. 491 
Declaration of interests 492 
20 
 
RPP has served as a consultant to Berlin-Chemie AG, GoodLife Fertility BV, and Institut 493 
Biochimique SA. TIMK has received personal fees from Berlin Chemie, Goodlife Healthcare, 494 
and Quidel. BV has received honoraria from Berlin-Chime. EO has received grants from the 495 
National Institutes of Health. TV has received grants from the Netherlands Organization for 496 
Health Research and Development. CD has received grants from the Chief Scientist Office 497 
(Scotland) and the British Heart Foundation. SMN has received grants from the Chief 498 
Scientist Office (Scotland) and reports grants and personal fees from Roche Diagnostics, 499 
during the conduct of the study. LC reported serving as a consultant to Pfizer. TM reported 500 
serving as a consultant to Abbott Diagnostics and Roche. ENP has received grants from the 501 
Sociedad Quimica y Minera de Chile and personal fees from the Institut Biochimique SA. The 502 
rest of the authors declare no competing interests. 503 
Acknowledgements 504 
We gratefully acknowledge the contribution of study participants across all cohorts included 505 
in the current study and extend our gratitude to study staff, data managers, general 506 
practitioners, hospitals and midwives who have made these separate studies possible. We also 507 
gratefully acknowledge the contributions of Shafqat Mukhtar MD (Department of 508 
Gynecology and Obstetrics, Shaikh Zayed Medical Complex, Lahore, Pakistan), Professor 509 
Andrew Hattersley, Beverley Shields PhD, Rachel Freathy PhD, Robin Beaumont PhD (all 510 
University of Exeter) to data collection and management, none of whom received any form of 511 
compensation.  512 
Funding 513 
This work was supported by a Replication Studies Grant (2016, number 401.16.020) from the 514 
Netherlands Organization for Scientific Research (NWO; grant to RPP, TIMK and EAPS). 515 
Cohort-specific grants are described in the appendix. None of the funders have been involved 516 
in the design and conduct of the study; collection, management, analysis, and interpretation of 517 
21 
 
the data; preparation, review, or approval of the manuscript; and decision to submit the 518 
manuscript for publication.  519 
 520 
References 521 
1. Zimmermann E, Gamborg M, Sorensen TI, Baker JL. Sex Differences in the Association 522 
Between Birth Weight and Adult Type 2 Diabetes. Diabetes 2015; 64(12): 4220-5. 523 
2. Zhang Z, Kris-Etherton PM, Hartman TJ. Birth weight and risk factors for cardiovascular 524 
disease and type 2 diabetes in US children and adolescents: 10 year results from NHANES. Matern 525 
Child Health J 2014; 18(6): 1423-32. 526 
3. Stuart A, Amer-Wahlin I, Persson J, Kallen K. Long-term cardiovascular risk in relation to birth 527 
weight and exposure to maternal diabetes mellitus. Int J Cardiol 2013; 168(3): 2653-7. 528 
4. Spracklen CN, Wallace RB, Sealy-Jefferson S, et al. Birth weight and subsequent risk of cancer. 529 
Cancer Epidemiol 2014; 38(5): 538-43. 530 
5. Geserick M, Vogel M, Gausche R, et al. Acceleration of BMI in Early Childhood and Risk of 531 
Sustained Obesity. New England Journal of Medicine 2018; 379(14): 1303-12. 532 
6. Khambalia AZ, Algert CS, Bowen JR, Collie RJ, Roberts CL. Long-term outcomes for large for 533 
gestational age infants born at term. J Paediatr Child Health 2017; 53(9): 876-81. 534 
7. Weissmann-Brenner A, Simchen MJ, Zilberberg E, et al. Maternal and neonatal outcomes of 535 
large for gestational age pregnancies. Acta Obstet Gynecol Scand 2012; 91(7): 844-9. 536 
8. Korevaar TIM, Medici M, Visser TJ, Peeters RP. Thyroid disease in pregnancy: new insights in 537 
diagnosis and clinical management. Nat Rev Endocrinol 2017; 13(10): 610-22. 538 
9. Monen L, Kuppens SM, Hasaart TH, et al. Maternal thyrotropin is independently related to 539 
Small for Gestational Age neonates at term. Clinical endocrinology 2015; 82(2): 254-9. 540 
10. Chen L-M, Du W-J, Dai J, et al. Effects of subclinical hypothyroidism on maternal and perinatal 541 
outcomes during pregnancy: a single-center cohort study of a Chinese population. PloS one 2014; 542 
9(10): e109364. 543 
11. Cleary-Goldman J, Malone FD, Lambert-Messerlian G, et al. Maternal thyroid hypofunction 544 
and pregnancy outcome. Obstetrics and gynecology 2008; 112(1): 85. 545 
12. Zhu Yd, Han Y, Huang K, et al. The impact of isolated maternal hypothyroxinaemia on the 546 
incidence of large‐for‐gestational‐age infants: the Ma'anshan Birth Cohort study. BJOG: An 547 
International Journal of Obstetrics & Gynaecology 2018; 125(9): 1118-25. 548 
13. Kumru P, Erdogdu E, Arisoy R, et al. Effect of thyroid dysfunction and autoimmunity on 549 
pregnancy outcomes in low risk population. Arch Gynecol Obstet 2015; 291(5): 1047-54. 550 
14. Maraka S, Ospina NM, O'Keeffe DT, et al. Subclinical Hypothyroidism in Pregnancy: A 551 
Systematic Review and Meta-Analysis. Thyroid 2016; 26(4): 580-90. 552 
15. Demailly R, Escolano S, Quantin C, Tubert-Bitter P, Ahmed I. Prescription drug use during 553 
pregnancy in France: a study from the national health insurance permanent sample. 554 
Pharmacoepidemiol Drug Saf 2017; 26(9): 1126-34. 555 
16. Engeland A, Bjorge T, Klungsoyr K, Hjellvik V, Skurtveit S, Furu K. Trends in prescription drug 556 
use during pregnancy and postpartum in Norway, 2005 to 2015. Pharmacoepidemiol Drug Saf 2018; 557 
27(9): 995-1004. 558 
17. Smolina K, Hanley GE, Mintzes B, Oberlander TF, Morgan S. Trends and Determinants of 559 
Prescription Drug Use during Pregnancy and Postpartum in British Columbia, 2002-2011: A 560 
Population-Based Cohort Study. PLoS One 2015; 10(5): e0128312. 561 
22 
 
18. Tinker SC, Broussard CS, Frey MT, Gilboa SM. Prevalence of prescription medication use 562 
among non-pregnant women of childbearing age and pregnant women in the United States: 563 
NHANES, 1999-2006. Matern Child Health J 2015; 19(5): 1097-106. 564 
19. Nishigori H, Obara T, Nishigori T, et al. Drug Use before and during Pregnancy in Japan: The 565 
Japan Environment and Children's Study. Pharmacy (Basel) 2017; 5(2). 566 
20. Haddow JE, Craig WY, Neveux LM, et al. Implications of High Free Thyroxine (FT4) 567 
concentrations in euthyroid pregnancies: the FaSTER trial. J Clin Endocrinol Metab 2014; 99(6): 2038-568 
44. 569 
21. Medici M, Timmermans S, Visser W, et al. Maternal thyroid hormone parameters during early 570 
pregnancy and birth weight: the Generation R Study. J Clin Endocrinol Metab 2013; 98(1): 59-66. 571 
22. Zhang C, Yang X, Zhang Y, et al. Association Between Maternal Thyroid Hormones and Birth 572 
Weight at Early and Late Pregnancy. J Clin Endocrinol Metab 2019. 573 
23. Johns LE, Ferguson KK, Cantonwine DE, Mukherjee B, Meeker JD, McElrath TF. Subclinical 574 
Changes in Maternal Thyroid Function Parameters in Pregnancy and Fetal Growth. J Clin Endocrinol 575 
Metab 2018; 103(4): 1349-58. 576 
24. Shields BM, Knight BA, Hill A, Hattersley AT, Vaidya B. Fetal thyroid hormone level at birth is 577 
associated with fetal growth. J Clin Endocrinol Metab 2011; 96(6): E934-8. 578 
25. Leon G, Murcia M, Rebagliato M, et al. Maternal thyroid dysfunction during gestation, 579 
preterm delivery, and birthweight. The Infancia y Medio Ambiente Cohort, Spain. Paediatr Perinat 580 
Epidemiol 2015; 29(2): 113-22. 581 
26. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid 582 
Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the 583 
Postpartum. Thyroid 2017; 27(3): 315-89. 584 
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Table Characteristics of the total study population (N=48,145*) 665 
Maternal characteristics  
Age, years 29·0 (5·1) [N=47,661] 
Gestational age at the time of sampling, weeks 12·8 (7·0 to 39·7) [N= 47,979] 
BMI, kg/m2 24·0 (4·4) [N=32,586†] 
Parity, N (%)  
0 24,589 (51·1) 
1 13,805 (28·7) 
2 4,400 (9·1) 
≥3 2,486 (5·2) 
Missing† 2,865 (6.0) 
Smoking status, N (%)  
Non/past smoker 39,788 (82·6) 
Current smoker 5,038 (10·5) 
Missing† 3,319 (6.9) 
Education, N (%)  
Low 10,085 (20·9) 
Medium 11,122 (23.1) 
High 11,744 (24·4) 
Missing† 15,194 (31.6) 
  
Maternal test results  
TSH (mU/L) 1·32 (0·13-4·50) [N=47,524] 
FT4 (pmol/L) 13·0 (7·3-21·9) [N=47,394] 
TPOAb positivity, N (%) 3,128 (7·5) [N=41,706] 
TgAb positivity, N (%) 1,063 (5·8) [N=18,355] 
  
Child characteristics  
Birth weight, grams 3,400 (536) 
Small for gestational age, N (%) 4,771 (9·9) 
Large for gestational age, N (%) 4,736 (9·8) 
Gestational age at birth, weeks 39·9 (35·5-42·0) 
Sex, N (%) [N=37,181] 
Female 19,644 (40.8) 
Male 19,054 (39.6) 
Missing† 9,447 (19.6) 
Table shows descriptive statistics of the characteristics of all included women as the 666 
mean (SD), median (95% range) or count (percentage), as appropriate. Cohort-specific 667 
descriptive characteristics are shown in appendix p10-13. 668 
*Number of participants with available data on either of thyroid function tests, unless 669 
otherwise indicated. 670 
† Missing mostly due to lack of data from one or some cohorts. 671 
For detailed description of missing data of covariates per cohort see appendix p14. 672 
 673 
Figure 1. Flowchart of the study and population selection. 674 
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Figure 2. Association of thyroid function test abnormalities with small or large for gestational 675 
age and birth weight. 676 
All analyses were adjusted for maternal age, BMI, ethnicity, smoking, parity, gestational age 677 
at blood sampling, fetal sex and gestational age at birth (the latter two for birth weight only). 678 
Risk differences and 95% CIs were back-calculated from the results of multivariable models 679 
and adjusted for baseline risk imprecision. 680 
Figure 3. Association of TSH and FT4 concentrations with small or large for gestational age 681 
and birth weight. 682 
Figures show the association of maternal TSH and FT4 in full range or within the normal 683 
range (2.5th-97.5th percentiles) with small or large for gestational age (panel A) and birth 684 
weight in grams (panel B). All analyses were adjusted for maternal age, BMI, ethnicity, 685 
smoking, parity, gestational age at blood sampling, fetal sex and gestational age at birth (the 686 
latter two for birth weight only). 687 
* After exclusion of outliers of TSH (n=453) or FT4 (n=169). 688 
† Normal range (2.5th-97.5th percentiles) is defined based on cohort-specific absolute 689 
measurements of TSH or FT4, which in the standardized data corresponds to TSH Z-score 690 
range of -4.2 to 1.8 and FT4 Z-score range of -2.2 to 2.5. 691 
Figure 4. Association of FT4 Z-scores with birth weight according to gestational age at the 692 
time of sampling. 693 
Figure shows the association of FT4 Z-scores with birth weight (grams) stratified by 694 
gestational age at the time of sampling. The analysis was adjusted for maternal age, BMI, 695 
ethnicity, smoking, parity, gestational age at blood sampling and fetal sex and gestational age 696 
at birth. 697 
